Related Experiment Video
Updated: Sep 22, 2025

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Erythema multiforme associated with anti-plakin antibodies: a multicentric retrospective case series
A Weill1,2,3, V Descamps4, F Chasset5
1Department of Dermatology, CHU Henri Mondor, AP-HP, Créteil, France.
Background:
Erythema multiforme (EM) is a muco-cutaneous inflammatory disease mainly triggered by herpes simplex virus (HSV) recurrences. Association of EM and circulating auto-antibodies against plakins (anti-PLK-Abs [EM-PLK+]) has been reported. However, little is known about this subset of EM.
Objectives:
We aimed to describe the clinical and immunological features and response to treatment of EM-PLK+.
Methods:
We conducted a retrospective multicentric study of EM-PLK+ selected from the database of the immunological laboratory of Bichat hospital, Paris, France, from January 2009 to December 2020. Anti-PLK-Abs were detected in ≥1 immunological tests: immunofluorescence assay, immunoblotting and/or ELISA. Patients with alternative diagnoses were excluded.
Results:
We included 29 patients (16 women, median age 25 [range 2-58] years). EM-PLK+ were mostly major (EM with ≥2 mucosal involvements; n = 24, 83%) and relapsing (≥2 flares; n = 23, 79%). Cutaneous lesions were target (n = 13, 54%) and target-like lesions (n = 9, 38%) with usual topography (acral, n = 19, 79%; limbs, n = 21, 88%). Mucosal lesions affected the mouth (n = 27, 96%) and genitalia (n = 19, 68%), with a median of 2 [range 0-5] mucous membranes. EM-PLK+ were suspected as certain or possible postherpetic (EM-HSV) in 19 cases (65.5%); no triggering factors were detected in 9 (31%) patients. Desmoplakin-I/II Abs were the most frequent anti-PLK-Abs (n = 20, 69%); envoplakin and periplakin Abs were detected in 11 and 9 cases. Relapsing EM-PLK+ (n = 23) were still active (≥1 flare within 6 months) in 13 (57%) patients despite immunosuppressive therapy (n = 8, 62%). Antiviral drugs were ineffective in preventing relapse in 15/16 (94%) EM-HSV.
Conclusion:
The rationale for anti-PLK-Ab detection in EM is not elucidated. More systematic research of anti-PLK-Abs is warranted to better understand whether this association reflects humoral immune activity in a subset of EM or is fortuitous, related to an epitope spreading process. However, EM-PLK+ seems to be associated with major and relapsing subtypes, and difficult-to-treat cases.
Insights
Erythema multiforme with auto-antibodies against plakins (EM-PLK+) is often severe and recurrent. These difficult-to-treat cases highlight the need for further research into anti-PLK-Abs in EM.
Area of Science:
- Immunodermatology
- Autoimmunity
- Mucocutaneous diseases
Background:
- Erythema multiforme (EM) is an inflammatory condition often triggered by herpes simplex virus (HSV).
- A subset of EM patients exhibit auto-antibodies against plakins (anti-PLK-Abs), termed EM-PLK+.
- Clinical and immunological characteristics of EM-PLK+ remain poorly understood.
Purpose of the Study:
- To delineate the clinical and immunological features of EM-PLK+.
- To evaluate the treatment response in EM-PLK+ patients.
- To investigate the association between EM and anti-PLK-Abs.
Main Methods:
- Retrospective multicentric study (January 2009 - December 2020).
- Selection of EM-PLK+ patients from Bichat hospital's immunological laboratory database.
- Detection of anti-PLK-Abs via immunofluorescence assay, immunoblotting, and/or ELISA; exclusion of alternative diagnoses.
Main Results:
- 29 EM-PLK+ patients included (83% major EM, 79% relapsing EM).
- Typical lesions observed: targetoid (54%) and target-like (38%) cutaneous lesions; frequent oral (96%) and genital (68%) mucosal involvement.
- Desmoplakin-I/II Abs were most common (69%); 57% of relapsing cases remained active despite treatment; antivirals were ineffective in preventing EM-HSV relapses (94%).
Conclusions:
- The role of anti-PLK-Abs in EM requires further elucidation.
- Systematic research into anti-PLK-Abs may clarify their association with EM pathogenesis (humoral immunity vs. epitope spreading).
- EM-PLK+ is associated with severe, relapsing, and treatment-resistant forms of EM.
Related Concept Videos
Cytoskeletal Linker Proteins - Plakins
Endocarditis II: Clinical Features of Infective Endocarditis
Myocarditis II: Clinical Features and Diagnostic Tests
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction

